Nederlands tijdschrift voor geneeskunde · 2026
[Insulin intoxications caused by falsified semaglutide].
СтатьяКлинический случайАннотация на английскомНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Stammers Julian, Hofste Op Bruinink Davine, Karel Peter G A, van der Hoeven Casper J, Schol-Gelok Suzanne, Stam-Slob Manon C
Аннотация
BACKGROUND: Treatment with glucagon-like peptide-1 receptor agonists such as semaglutide is generally subject to strict reimbursement criteria. This leads to a growing off-label market outside of the regular healthcare system without strict quality controls, which may jeopardize patient safety.
CLINICAL CONTEXT: Two cases are reported of patients without diabetes or obesity, who had injected semaglutide subcutaneously that was obtained without a prescription. Both presented in a coma with severe hypoglycemia, hypokalemia and hypothermia, which was caused by an intoxication with synthetic insulin. Monotherapy with semaglutide is not associated with significant hypoglycemia in healthy individuals. Up to two days of continuous glucose infusion was required to keep patients euglykemic.
CONCLUSION: The use of illegally obtained semaglutide may lead to life-threatening intoxications, due to insufficient safety precautions for the provided medication. Timely notification of cases to the national health regulatory authority is essential to mitigate further distribution of falsified drugs.
CLINICAL CONTEXT: Two cases are reported of patients without diabetes or obesity, who had injected semaglutide subcutaneously that was obtained without a prescription. Both presented in a coma with severe hypoglycemia, hypokalemia and hypothermia, which was caused by an intoxication with synthetic insulin. Monotherapy with semaglutide is not associated with significant hypoglycemia in healthy individuals. Up to two days of continuous glucose infusion was required to keep patients euglykemic.
CONCLUSION: The use of illegally obtained semaglutide may lead to life-threatening intoxications, due to insufficient safety precautions for the provided medication. Timely notification of cases to the national health regulatory authority is essential to mitigate further distribution of falsified drugs.